Home » Topics » BioWorld Science

BioWorld Science
RSS

Venadaparib shows safety and preliminary efficacy in first-in-human trial

July 6, 2021

Mersana starts phase I/II umbrella study of XMT-1536 in high-grade serous ovarian cancer

July 6, 2021

Enrollment ongoing in phase I/II study of PVSRIPO

July 6, 2021

DPP3 is a marker of severity in heart failure

July 5, 2021

Transcenta reports antitumor responses with TST-001 in gastric cancer

July 5, 2021

Initiation of phase II study of HA-121-28 in advanced biliary tract cancer

July 5, 2021

SHR-1314 studied in phase II/III trial for active ankylosing spondylitis

July 5, 2021

Phase Ib data presented for ulixertinib plus palbociclib in advanced solid tumors

July 5, 2021

GNT-0003 restores UGT1A1 expression in patients with Crigler-Najjar syndrome

July 5, 2021

Sperogenix to develop Abbisko's ABSK-021 for rare neurological diseases in China

July 5, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...